NEW YORK (GenomeWeb) – Targos will provide its expertise, biomarker services, and quality standards to support WuXi PharmaTech's bioanalytical work for pharmaceutical customers as part of a biomarker collaboration announced today by the companies.

Targos and WuXi will focus on validating and analyzing clinical tissue biomarkers in cancer, they said, adding Targos is providing training and education to help pathologists and histotechnologists produce accurate, objective, and reproducible diagnostic results.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.